Registered Trials
-
NCT04990466
Phase 2/3Total Enrollment: 550
Official Trial Registration:
-
NCT04608305
Phase 1/2Israel
Total Enrollment: 1,040
Official Trial Registration:
Vaccine Type: Replicating Viral Vector
This vaccine may also be referred to as IIBR-100
This vaccine has reached Phase 3 trials.
This vaccine is not yet approved.
Total Enrollment: 550
Israel
Total Enrollment: 1,040
© 2022 VIPER Group COVID19 Vaccine Tracker Team
Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)
This site is provided for informational purposes only based on publically available data.